GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Doseology Sciences Inc (OTCPK:DOSEF) » Definitions » Net Income

DOSEF (Doseology Sciences) Net Income : $-0.20 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Doseology Sciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Doseology Sciences's Net Income for the three months ended in Dec. 2024 was $-0.04 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.20 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Doseology Sciences's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $-0.01.


Doseology Sciences Net Income Historical Data

The historical data trend for Doseology Sciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Doseology Sciences Net Income Chart

Doseology Sciences Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
Net Income
-0.32 -1.33 -1.51 -1.34 -0.25

Doseology Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.03 -0.08 -0.05 -0.04

Doseology Sciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Doseology Sciences's Net Income for the fiscal year that ended in Jun. 2024 is calculated as

Net Income(A: Jun. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.248+0+0+0
=-0.25

Doseology Sciences's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.041+0+0+0
=-0.04

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Doseology Sciences  (OTCPK:DOSEF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Doseology Sciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Doseology Sciences Net Income Related Terms

Thank you for viewing the detailed overview of Doseology Sciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Doseology Sciences Business Description

Traded in Other Exchanges
Address
9-3151 Lakeshore Road, Suite 305, Kelowna, BC, CAN, V1W 3S9
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the focus of making a meaningful impact on the mental health pandemic and improving overall health. Geographically earns it revenue from Canada.

Doseology Sciences Headlines

From GuruFocus

Doseology Opens to American Investors

By PRNewswire PRNewswire 06-01-2022

Doseology Uplists to OTCQB Market in USA

By PRNewswire PRNewswire 07-06-2022

Doseology Opens to American Investors

By PRNewswire PRNewswire 07-01-2022

Doseology Announces CEO Transition

By PRNewswire PRNewswire 03-31-2023

Doseology Announces New Director and Corporate Secretary

By PRNewswire PRNewswire 05-05-2023

Doseology Welcomes New CFO

By PRNewswire PRNewswire 03-03-2023

Doseology Provides Corporate Update

By PRNewswire PRNewswire 01-23-2023

Doseology Opens to American Investors

By PRNewswire PRNewswire 06-21-2022

Doseology Opens to American Investors

By PRNewswire PRNewswire 06-11-2022